Previous Pause Next
Home >> News Center >> Investment & Financials >>
Investment & Financials
Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers PDF Print E-mail
Wednesday, 07 March 2012 06:42 DIEGO, March 6, 2012 - Aragon Pharmaceuticals today announced that the company has secured $42 million in an oversubscribed Series C financing to advance Aragon's pipeline of therapies targeting hormone-driven cancers, including ARN-509, the company's lead compound for the treatment of castration-resistant prostate cancer (CRPC).
Karyopharm Therapeutics Raises $10 Million More in Series A Round PDF Print E-mail
Thursday, 03 November 2011 07:00, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export(SINE) for various cancers. The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.
Roche, Forbion Invest in MDx Firm Curetis PDF Print E-mail
User Rating :  / 1
Thursday, 27 October 2011 05:44
Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.

Roche Venture Fund and Dutch venture capital firm Forbion Capital Partners led the round. CD-Venture and Curetis' management were also participants.

Merck Joins the Big Pharma VC Party, Setting Up $250M Biotech Investment Fund PDF Print E-mail
Monday, 19 September 2011 00:06
Just about all the major pharmaceutical companies have their own venture capital funds to invest in biotech startups, and now one of the real biggies, Whitehouse Station, NJ-based Merck, has joined the club.
Innospec Initiates a $40 Million Share Repurchase Program PDF Print E-mail
Saturday, 10 September 2011 00:11
Innospec Inc. (Nasdaq:IOSP) today announced that its board of directors has approved an increase in the amount of shares that are subject to buy back under the company's stock repurchase program.
GlaxoSmithKline Gets $94 Million Contract for Antibiotic PDF Print E-mail
Friday, 09 September 2011 00:50
Anacor Pharmaceuticals /quotes/zigman/1553440/quotes/nls/anac ANAC +5.35% announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S.
Affymax, Inc. Receives $10 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKDG.DE) for FDA Filing of New Drug Application for Hematide(TM)/Peginesatide PDF Print E-mail
Saturday, 13 August 2011 00:21
Affymax, Inc. (Nasdaq:AFFY - News) today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients.
Paladin Labs Inc. Makes Takeover Bid for Afexa Life Sciences Inc. Worth $56.7 Million PDF Print E-mail
Friday, 12 August 2011 00:06
Paladin Labs Inc. ("Paladin" or the "Company") /quotes/zigman/14723 CA:PLB +3.73% , a leading Canadian diversified specialty pharmaceutical company, today announced that it is making an offer to acquire any and all of the issued and outstanding shares of Afexa Life Sciences Inc. ("Afexa") /quotes/zigman/42940 CA:FXA +17.90% of Edmonton,
Merck Receives Subpoena Related to Selling Three Medicines PDF Print E-mail
Thursday, 11 August 2011 00:09

Merck & Co., the second-largest U.S. drugmaker, received a subpoena from the Department of Justice related to the sales of cancer and antiviral drugs.

Pfizer Inc., University of California, San Diego Ink $50 Million Drug Discovery Pact PDF Print E-mail
Wednesday, 10 August 2011 00:03

A new drug research collaboration between pharmaceutical giant Pfizer and the University of California San Diego could deliver up to $50 million to local scientists over the next five years, speed the delivery of promising therapies to patients and help refill the fast-depleting pipeline of the world’s largest drugmaker.

Rempex Pharmaceuticals, Inc. Snags $67.5 Million PDF Print E-mail
Thursday, 10 November 2011 06:16
SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing. New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round. This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.
Selecta Biosciences, Inc. Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies PDF Print E-mail
Friday, 28 October 2011 06:19
WATERTOWN, Mass.--(BUSINESS WIRE)-- Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that it has secured new funding from RUSNANO, existing investors, and additional new investors. RUSNANO, a $10-billion Russian Federation fund that supports nanotechnology advances, entered as a significant new investor in Selecta in this new $47.25 million financing which will broaden Selecta’s research and development (R&D) capabilities and advance its new class of vaccines and immunotherapies.
Dermira Scores $42 Million Series A Financing to Fund Therapeutic Advances in Dermatology PDF Print E-mail
Sunday, 23 October 2011 00:58
REDWOOD CITY, Calif., Oct 20, 2011 (BUSINESS WIRE) -- Dermira today announced a $42 million Series A financing to support the acquisition, development and commercialization of novel therapeutics in dermatology. The company was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams, including Tom Wiggans, who will serve as Chief Executive Officer, and Dr. Eugene Bauer, who will serve as Chief Medical Officer, together with Bay City Capital. They are joined by Chris Griffith, previously at Gilead and Bay City Capital, who will serve as the Vice President of Corporate Development and Strategy, and Luis Pena, previously at Stiefel, a GSK Company, who will serve as the Vice President of Product Development.
VentiRx Pharmaceuticals, Inc. Concentrates on Cancer Development to Conserve Cash PDF Print E-mail
Saturday, 17 September 2011 00:38

For its first five years, VentiRx Pharmaceuticals had an unusual setup in which it was based in two places, with a drug development team in Seattle, and the business and administrative operation in San Diego. Now it’s all being merged together in Seattle, as the company looks to conserve cash and concentrate its efforts on doing one thing well—cancer drug development.

Orphazyme Raises $19.6 Million in a Series A Financing Round PDF Print E-mail
Friday, 09 September 2011 00:52
Orphazyme ApS, a biopharmaceutical company which develops innovative treatments for a family of genetic disorders called lysosomal storage diseases, today announced the successful completion of a €14 million Series A financing round
China's Government Spent $39 Billion on Healthcare in 1st Half of 2011 PDF Print E-mail
Tuesday, 30 August 2011 00:32

The central government of the PRC spent 245 billion RMB ($38.4 billion) on healthcare in the first half of 2011, an increase of 61% from 2010, according to a report submitted to the country’s governing body.

Enobia Pharma Raises US $40 Million PDF Print E-mail
Friday, 12 August 2011 00:07
Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US $40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors.
NeoStem, Inc. Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis PDF Print E-mail
Thursday, 11 August 2011 00:27
NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell based therapeutics development, today announced that the Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP) has awarded NeoStem $1,780,049 to be applied towards funding the Company's VSEL Technology.
Vectura Extends Novartis Deal For VR315 Lung Drug PDF Print E-mail
Wednesday, 10 August 2011 00:19

U.K. drug company Vectura Group PLC (VEC.LN) Friday said it has signed a licensing deal with Novartis AG (NOVN.VX) for its generic asthma medicine VR315, covering markets outside Europe and North America.

PETA Loses Lawsuit Over Merck & Co., Inc. Shareholder Proposal PDF Print E-mail
Tuesday, 09 August 2011 01:17

U.S. District Judge Amy Jackson dismissed a lawsuit filed by People for the Ethical Treatment of Animals seeking a court order to force Merck & Co. Inc. to include a resolution from the animal rights group in materials for the pharmaceutical company’s annual shareholder meeting.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 67